R&D Investment and Business Restructuring in the Anti-Fatigue and Femtech Fields
First written in FY2024. 2 of 5 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「In the current consolidated fiscal year, the Group conducted R&D activities to develop new functional materials and expand its product lineup, primarily through the Fatigue Project launched in October 2003 and a joint research agreement with The Jikei University School of Medicine entered into in April 2024. Total R&D expenses amounted to ¥29 million.」
R&D into functional materials and products, including anti-fatigue and femtech applications, continued, and total R&D expenses for the fiscal year amounted to ¥29 million. - FY2026-H1RestatedAnnual report
「In the current interim consolidated accounting period, sales remained at approximately the same level as in the year-earlier period, mainly because sales of existing OEM products and orders related to femtech remained solid.」
Orders related to femtech have remained solid, reaffirming the policy of expanding into this field. - FY2025AdvancedAnnual report
「In the current consolidated fiscal year, the Group conducted R&D activities to develop new functional materials and expand its product lineup, primarily through the Fatigue Project launched in October 2003 and a joint research agreement with The Jikei University School of Medicine entered into in April 2024. Total R&D expenses amounted to ¥57 million.」
The Company continued to invest in R&D in the anti-fatigue and femtech fields, recording ¥57 million in R&D expenses for the Fatigue Project, joint research with The Jikei University School of Medicine, and the development of new functional materials and products. - FY2025-H1AdvancedAnnual report
「In the current interim consolidated accounting period, sales increased because, while the sales volume of raw materials remained at the same level as in the year-earlier period, sales of existing OEM products and new orders related to femtech were strong.」
Regarding the expansion into the femtech field announced for FY2024, the disclosure states that new orders related to femtech were strong, identifying this specifically as a driver of higher sales in the functional materials development business. - FY2024First statedAnnual report
「The Group will return to its fundamental mission of helping people lead healthy and safe lives and contributing to lower medical costs and improved quality of life by building and applying its core strength in evidence across a range of fields. Leveraging its extensive network in the medical and academic communities, the Group will focus on R&D to expand into the anti-fatigue and femtech businesses, and is working to make the fiscal year ending June 2025 a consolidated fiscal year of returning to its roots and restructuring its businesses.」
Against the backdrop of weak performance, the Company has for the first time clearly stated a policy of returning to its roots with evidence as the foundation and investing in R&D to expand into the anti-fatigue business and, newly, the femtech business.